Obesity is not a choice. Those with overweight or obesity face both stigma and increased risks for type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and some cancers. In 2017–2018, ...

The bathroom scale doesn’t lie, but your body might be working against you behind the scenes. Exciting new research reveals that fat cells possess a remarkable ability to “remember” their former size, ...

People who take GLP-1 weight-loss medications and then stop them are likely to experience strong metabolic rebound, including ...

Overweight and obese individuals who lose and then regain weight are at risk of detrimental changes to body composition, with a progressive gain of fat mass and loss of non-fat mass, according to a ...

*Please mention the European Congress on Obesity when using this story* New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits of ...

Obesity affects over half of the global adult population and contributes to millions of deaths each year from diseases like cardiovascular disorders, type 2 diabetes, and fatty liver disease. Overview ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a new study finds. The research review, published on Tuesday in the journal BMC ...

Weight-loss injections such as Mounjaro containing tirzepatide and Wegovy containing semaglutide have demonstrated strong ...

Scientists discovered that people taking weight loss medications regained pounds weeks after they stopped taking the drugs. More than 1,000 people participated in a study and their lifestyle habits ...

--Veru has been granted a meeting with FDA to discuss the Phase 3 clinical program-- MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ...

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; ...

MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...